Overview

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.

Phase:

Phase 2

Details

Lead Sponsor:

Pierre Fabre Medicament

Collaborators:

Array BioPharma
Merck KGaA, Darmstadt, Germany
Ono Pharmaceutical Co. Ltd
Pfizer

Treatments:

Cetuximab